Actively Recruiting
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
Led by University of Alberta · Updated on 2026-01-20
870
Participants Needed
1
Research Sites
358 weeks
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
U
University Hospital Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU. This LIBERATE multi-site study will continue the work of the LIBERATE feasibility RCT study to evaluate the role of midodrine for patients with low blood pressure in the ICU. It is comprised of the multi centre pilot RCT followed by the definitive multi centre RCT.
CONDITIONS
Official Title
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Currently receiving vasopressor support
- Vasopressor dose is decreasing
You will not qualify if you...
- More than 24 hours have passed since peak vasopressor dose
- Contraindication to enteral medications
- Received midodrine in the last 7 days
- Expected death or planned withdrawal of life-sustaining therapy within 24 hours
- Pregnancy
- Known allergy to midodrine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T5R 0T1
Actively Recruiting
Research Team
D
Dawn Opgenorth, RN
CONTACT
O
Oleksa Rewa, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here